Analyst Price Target is $6.25
▲ +2,303.85% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Pear Therapeutics in the last 3 months. The average price target is $6.25, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 2,303.85% upside from the last price of $0.26.
Current Consensus is
The current consensus among 5 polled investment analysts is to hold stock in Pear Therapeutics.
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.